SCHEDULE 13G: Vanguard Group Discloses 5.58% Stake in OnKure Therapeutics Inc.
Beneficial Ownership Report
The Vanguard Group, a major investment adviser, has reported a beneficial ownership of 5.58% in OnKure Therapeutics Inc.'s Common Stock as of December 31, 2024.
Summary
- The Vanguard Group has filed a Schedule 13G, indicating beneficial ownership of OnKure Therapeutics Inc. Common Stock.
- As of December 31, 2024, Vanguard beneficially owned an aggregate of 706,733 shares of OnKure Therapeutics Inc. Common Stock.
- This ownership represents 5.58% of the class of securities.
- Vanguard holds sole dispositive power over 705,988 shares and shared dispositive power over 745 shares.
- Vanguard holds no sole or shared voting power over these shares.
- The filing was made by The Vanguard Group, headquartered at 100 Vanguard Blvd., Malvern, PA 19355, and classified as an Investment Adviser (IA).
Sentiment
Score: 7
Explanation: The disclosure of a significant stake by a major institutional investor like Vanguard is generally perceived as a positive signal for the company, indicating institutional confidence and potentially attracting further investor interest.
Positives
- The disclosure of a significant stake (5.58%) by a major institutional investor like The Vanguard Group can be viewed positively, signaling institutional confidence in OnKure Therapeutics Inc.
Future Outlook
NA
Industry Context
This filing reflects a standard disclosure of institutional ownership in a publicly traded company within the biotechnology or pharmaceutical sector. Large investment firms like Vanguard routinely acquire significant passive stakes in companies for their various funds and managed accounts, indicating their investment in the broader market or specific industry segments.
Stakeholder Impact
- Shareholders: May view the significant institutional ownership as a positive indicator of the company's long-term prospects and stability, potentially influencing share price positively.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (reporting period end date) |
| 01/31/2025 | Date of signature for the Schedule 13G filing |
Keywords
OnKure Therapeutics Inc., Vanguard Group, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Investment Adviser, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.